Inspection Readiness is not an option – now, more than ever, it is urgent.
Our team of experts is equipped to guide you through every step of any inspection your firm is facing, with experience and expertise. The overview below outlines how ProPharma supports clients through every stage of the inspection readiness lifecycle.
We ensure that every step towards Inspection Readiness is carefully calibrated to your needs. Our method is backed by tangible tools and training programs developed from the ground up, tailored not just to your product, but to your organization's unique scale and scope. This approach allows you to maintain focus on running your business, while we dedicate ourselves fully to your Inspection Readiness, making it our singular priority.
Secure Your Regulatory Inspection Success
On average a new product takes approximately 10-15 years to develop, whether it is a biologic, a pharmaceutical product, a medical device, or a combination thereof.
- Can you risk the time and resources you invested in development by ignoring the importance of Inspection Readiness for a new product?
- Can you risk having an existing product off the market for remediation activities following a For Cause Inspection?
- Can your patients?
ProPharma's expertise covers all aspects of Inspections. Inspection Readiness Evaluation, Project Management, your Inspection Program/Process, Logistics, and Training – are just some of the most important areas of Inspection Readiness. Our expertise can become your greatest asset. We are eager to become your partner in navigating this critical process.
PAI Readiness
Pre-approval Inspections are one of the most critical inspections any Biologic, Pharmaceutical or Medical Device firm will undertake. Failure to meet FDA expectations can have a huge impact on organizations, including:
- Delays to product launch.
- Thousands, if not millions of dollars, in remediation costs.
- Lost market share.
- Loss of a firm's credibility.
PAI readiness is critical, and ProPharma is an industry leader in providing PAI Readiness to our clients.
BIMO Readiness
BIMO inspection readiness is essential for sponsors to ensure compliance with FDA regulations, protect data integrity, and uphold patient safety standards. By preparing thoroughly, sponsors:
- Ensure compliance with FDA regulations.
- Protect data integrity.
- Uphold patient safety standards.
- Help avoid costly delays.
- Prevent potential compliance issues.
- Facilitate smoother FDA inspections.
News & Insights
June 10, 2026
FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...
Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.
June 8, 2026
Modernizing Case Management for Global Compliance
Discover how E2B (R3) is modernizing pharmacovigilance case management, improving compliance, and streamlining adverse event reporting across global regulatory authorities.
June 4, 2026
Accelerating European Market Entry: The Strategic Advantage of Using FDA Approva...
Learn how the UK's IRP can help FDA-approved therapies achieve faster UK market access, accelerate launch sequencing, and support global regulatory strategy.
.png?width=320&height=185&name=BLA%20Case%20Study%20-%20Clinical%20Hold%20to%20Approval%20(RS).png)
.png?width=320&height=185&name=4%20-%20Quality%20%26%20Compliance%20(650%20x%20425%20px).png)
.png?width=320&height=185&name=Webinar%20Thumbnail%20Quality%20%26%20Compliance%20(650%20x%20425%20px).png)
News & Insights
May 27, 2026
ProPharma Appoints Adrian Pencak as Chief Commercial Officer
ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
December 11, 2025
ProPharma Expands Operations with New Office in Hyderabad
ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.
